![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
C-SWIFT: Grazoprevir (MK-5172) + Elbasvir (MK-8472) + Sofosbuvir in Treatment-Naïve Patients with Hepatitis C Virus Genotype 1 Infection, With and Without Cirrhosis, for Durations of 4, 6 or 8 Weeks (Interim Results)
|
|
|
Reported by Jules Levin
AASLD 2014 Boston Nov 9
![AASLD1.gif](../images/111014/111014-5/AASLD1.gif)
![AASLD2.gif](../images/111014/111014-5/AASLD2.gif)
![AASLD3.gif](../images/111014/111014-5/AASLD3.gif)
![AASLD4.gif](../images/111014/111014-5/AASLD4.gif)
![AASLD5.gif](../images/111014/111014-5/AASLD5.gif)
![AASLD6.gif](../images/111014/111014-5/AASLD6.gif)
![AASLD7.gif](../images/111014/111014-5/AASLD7.gif)
![AASLD8.gif](../images/111014/111014-5/AASLD8.gif)
![AASLD9.gif](../images/111014/111014-5/AASLD9.gif)
![AASLD10.gif](../images/111014/111014-5/AASLD10.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|